Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice

BACKGROUND: The TLR9 agonist CpG is increasingly applied in preclinical and clinical studies as a therapeutic modality to enhance tumor immunity. The clinical application of CpG appears, however, less successful than would be predicted from animal studies. One reason might be the different administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nierkens, Stefan, den Brok, Martijn H., Roelofsen, Thijs, Wagenaars, Jori A. L., Figdor, Carl G., Ruers, Theo J., Adema, Gosse J.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791230/
https://www.ncbi.nlm.nih.gov/pubmed/20020049
http://dx.doi.org/10.1371/journal.pone.0008368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791230/
https://www.ncbi.nlm.nih.gov/pubmed/20020049
http://dx.doi.org/10.1371/journal.pone.0008368

Ejemplares similares